基于CiteSpace对肥厚型心肌病文献计量学分析

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (1883 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To visually analyze the scientific achievements in hypertrophic cardiomyopathy (HCM) by searching relevant literature. Methods The data were retrieved from Web of Science core collection database from January 2015 to December 2020. CiteSpace was used to make visual analysis of published HCM related literatures by country, institution, author, and keywords. Results From 2015 to 2020, a total of 6 032 articles related to HCM were published worldwide, and the International Journal of Cardiology had the largest number of articles. The United States had the most publications, the Mayo Clinic was the most influential scientific institution, and author IACOPO OLIVOTTO had the most publications. Key words analysis showed that sudden cardiac death, mutation, prevalence, diagnosis, and cardiovascular magnetic resonance were the current research hotspots. Conclusion The targeted gene therapy of hypertrophic cardiomyopathy is a research hotspot, and the epidemiological research of HCM, especially the genetic research is the research front. Further development in this field also requires increased research and cooperation worldwide.

Key words： Bibliometric analysis CiteSpace Hypertrophic cardiomyopathy Research hotspots

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xuesong WEI Yi SHI Shuqing SHI Jingjing HU Yuanhui

Cite this article:

ZHANG Xuesong WEI Yi SHI Shuqing SHI Jingjing HU Yuanhui. Bibliometric analysis on hypertrophic cardiomyopathy based on CiteSpace[J]. 中国医药导报, 2022, 19(23): 5-8,26.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I23/5

[1] Jensen MK，Havndrup O，Christiansen M，et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents：a 12-year follow-up study of clinical screening and predictive genetic testing [J]. Circulation，2013，127（1）：48-54.
[2] Maron BJ，Maron MS，Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years：clinical perspectives [J]. J Am Coll Cardiol，2012，60（8）：705-715.
[3] Khan MS，Ullah W，Riaz IB，et al. Top 100 cited articles in cardiovascular magnetic resonance：a bibliometric analysis [J]. J Cardiovasc Magn Reson，2017，18（1）：87.
[4] Grundvold I，Skretteberg PT，Liestol K，et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men：a 35-year follow-up study [J]. Hypertension，2012，59（2）：198-204.
[5] 中华医学会心血管病学分会，中国成人肥厚型心肌病诊断与治疗指南编写组，中华心血管病杂志编辑委员会.中国成人肥厚型心肌病诊断与治疗指南[J].中华心血管病杂志，2017，45（12）：1015-1032.
[6] Insewo DAE，Olayeye I，Bakinde N. Differentiating Left Ventricular Hypertrophy in Athletes from That in Patients With Hypertrophic Cardiomyopathy [J]. Am J Cardiol，2015， 115（4）：555.
[7] 林薿，李春梅，尹立雪，等.三维斑点追踪超声心动图对肥厚型心肌病患者左心室心肌力学研究[J].西部医学，2014，26（4）：458-463.
[8] Delgado V，Bax JJ. Clinical topic：Nuclear imaging in hypertrophic cardiomyopathy [J]. J Nucl Cardiol，2015，22（3）：408-418.
[9] Fokstuen S，Munoz A，Melacini P，et al. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice [J]. J Med Genet，2011，48（8）：572-576.
[10] Sherrid MV，Shetty A，Winson G，et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil [J]. Circ Heart Fail，2013，6（4）：694-702.
[11] Abozguia K，Elliott P，Mckenna W，et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy [J]. Circulation，2017，122（16）：1562-1569.
[12] Flenner F，Friedrich FW，Ungeheuer N，et al. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes，but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy [J]. Cardiovasc Res，2016，1（109）：90-102.
[13] Dearani JA，Ackerman MJ. Treating obstructive hypertrophic cardiomyopathy—what’s best，what’s next? [J]. J Thorac Cardiovas Surg，2016，152（4）：988-990.
[14] Okutucu S，Aytemir K，Oto A. Glue septal ablation：A promising alternative to alcohol septal ablation [J]. JRSM Cardiovasc Dis，2016，5（3）：401146265.
[15] Maron BJ，Rowin EJ，Casey SA，et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies [J]. J Am Coll Cardiol，2015，65（18）：1915-1928.
[16] Li J，Mamidi R，Doh CY，et al. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC deficient mice [J]. JCI Insight，2020，5（17）：e130182.
[17] Gedicke-Hornung C，Behrens-Gawlik V，Reischmann S，et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice [J]. Embo Molecul Med，2013，5（7）：1128-1145.
[18] 马冲，王忠良，闫家兵.肥厚型心肌病中医药研究进展[J].家庭生活指南，2021（3）：160-162.
[19] 王然勤，陈建强，马珠群，等.血府逐瘀汤治疗肥厚型心肌病27例[J].辽宁中医杂志，2002，29（8）：467-468.
[20] 钱小奇，陈红，金泽秋.生脉四物汤对肥厚型心肌病IGF-1的影响[J].中西医结合心脑血管病杂志，2004，2（8）：440-441.
[21] 兰玥，马丽红.保元汤合苓桂术甘汤治疗肥厚型心肌病伴心律失常治验1例报道[J].中西医结合心脑血管病杂志，2018，16（9）：152-154.
[22] 刘金凤，徐利亚，陈靖，等.刘如秀教授治疗肥厚型心肌病经验总结[J].世界中西医结合杂志，2014，9（3）：229-231.
[23] 陈鹏，刘永胜，陈刚，等.消心痹方联合卡维地洛治疗肥厚型心肌病的临床研究[J].中西医结合心脑血管病杂志，2019，17（8）：1133-1137.
[24] 阎雅芳，梁艳敏，韩振祥，等.通心络胶囊治疗原发性肥厚型心肌病疗效观察[J].中国社区医师：医学专业，2009， 11（8）：78.
[25] 邰秀洋.益心舒胶囊与富马酸比索洛尔联合治疗肥厚性心肌病的临床观察[J].临床合理用药杂志，2014，7（21）：127-128.
[26] 丁海英，朱维葵，卢南云，等.步长脑心通治疗肥厚型心肌病1例[J].福建医药杂志，2003，25（5）：187-188.
[27] 张杰杰，张金国.中药单体在抗心肌肥厚方面的相关研究进展[J].中国处方药，2021，19（11）：74-76.
[28] 吴松，王华，李佳，等.电针“内关”对心肌肥厚模型大鼠心肌形态学的影响[J].湖北中医杂志， 2015，37（6）：23-24.
[29] 吴松，王华，唐宏图，等.电针内关，神门对心肌肥厚模型大鼠AngⅡ和ET影响的比较研究[J].中华中医药杂志，2015，30（1）：42-45.